- Home
- SNX vs TECH Comparison
SNX vs TECH Comparison
Compare SNX & TECH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNX
- TECH
- Stock Information
- Founded
- SNX 1980
- TECH 1976
- Country
- SNX United States
- TECH United States
- Employees
- SNX N/A
- TECH N/A
- Industry
- SNX Retail: Computer Software & Peripheral Equipment
- TECH Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SNX Technology
- TECH Health Care
- Exchange
- SNX Nasdaq
- TECH Nasdaq
- Market Cap
- SNX N/A
- TECH 8.0B
- IPO Year
- SNX 2003
- TECH 1989
- Fundamental
- Price
- SNX $105.29
- TECH $49.00
- Analyst Decision
- SNX Strong Buy
- TECH Buy
- Analyst Count
- SNX 9
- TECH 9
- Target Price
- SNX $137.22
- TECH $81.25
- AVG Volume (30 Days)
- SNX 1.7M
- TECH 2.1M
- Earning Date
- SNX 03-27-2025
- TECH 05-07-2025
- Dividend Yield
- SNX 1.70%
- TECH 0.64%
- EPS Growth
- SNX 16.43
- TECH N/A
- EPS
- SNX 8.00
- TECH 0.98
- Revenue
- SNX $59,008,890,000.00
- TECH $1,196,016,000.00
- Revenue This Year
- SNX $4.62
- TECH $8.19
- Revenue Next Year
- SNX $4.85
- TECH $8.85
- P/E Ratio
- SNX $12.98
- TECH $51.32
- Revenue Growth
- SNX 4.62
- TECH 4.46
- 52 Week Low
- SNX $92.23
- TECH $46.44
- 52 Week High
- SNX $145.10
- TECH $85.57
- Technical
- Relative Strength Index (RSI)
- SNX 40.68
- TECH 35.22
- Support Level
- SNX $102.01
- TECH $46.44
- Resistance Level
- SNX $105.01
- TECH $53.00
- Average True Range (ATR)
- SNX 4.53
- TECH 3.26
- MACD
- SNX 1.06
- TECH -0.22
- Stochastic Oscillator
- SNX 76.79
- TECH 20.05
About TECH Bio-Techne Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.